993. Antibiotic consumption from 2013to 2015 at Colombian hospitals of third level of complexity.
Session: Poster Abstract Session: Antibiotic Stewardship: General Acute Care Implementation and Outcomes
Friday, October 28, 2016
Room: Poster Hall
  • POSTER IDWEEK,60517_25oct2016_F.pdf (258.5 kB)
  • Background: ABACIN (www.abacin.org) is a Colombian program of rational use of antibiotics, created and sponsored by the Colombian Association of Infectious Diseases (ACIN) since 2013 to improve the antibiotic stewardship in Colombia. Objective: monitor consumption of antibiotics in hospitals of third level around the country.

    Methods: Health Institutions interested in the surveillance and control of antibiotic use were invited to participate. An electronic online tool for entering data prescription of antibiotics was designed, according to the occupancy percentage, number of beds and number of antibiotics (blisters month per month). monitoring antibiotic consumption was the ATC/DDD system, and the unit of measurement was Defined Daily dose /100 occupied bed-days (DDD/100 OBD) during the period 2013-2015.

    Results: 11 institutions (5 from Bogotá D.C. and 6 from another cities) reported data from The top 5 most common antibiotics were: meropenem, vancomycin, cefepime, ceftriaxone and ciprofloxacin. The general average of DDD/100 OBD of antibiotics consumption from all institutions was 78,5 for 2013, 50.6 for 2014 and 45,6 for 2015. The average of DDD/100 OBD of the most common antibiotics was 0,23 for meropenem, 1,45 for vancomycin, 2,37 for cefepime, 1,47 for ceftriaxone and 0.71 for ciprofloxacin. Our findings describe an increase in expected value of some antibiotics such as Meropenem, Cefepime and Ceftriaxone in the period analyzed. 

    Conclusion: Despite the decline in total consumption of antimicrobials meropenem, ceftriaxone and cefepime presented an Increase in the tendency of use in the participating institutions. Our data findings provide baseline information on patterns of antibiotic consumption in Colombia and to correlate these findings with results of antibiotic susceptibility testing would provide insights and tools needed to support surveillance strategies and prudent use of antibiotics. Disclosures: This project has the financial support of ACIN. The authors declare no conflict of interest and isn´t supported by any pharmaceutical company

    Carlos Alvarez, MD; FIDSA, Internal Medicine, Universidad Nacional de Colombia, Bogotá, Colombia, Carlos Gomez, MD, ABACIN program, Bogotá, Colombia; Infectious Diseases, Clínica de la Mujer, Bogotá, Colombia, Anita Montañez, BSc, ABACIN Program, Bogotá, Colombia, Diego Ballen, MD, ABACIN PROGRAM, Bogotá, Colombia, Sandra Liliana Valderrama Beltran, MD, Infectious Diseases, hospital universitario san ignacio, bogota, Colombia, Sandra Gualteros, MD, Infectology, Fundación Clínica Abbot Shaio, Bogotá, Colombia, Karen Ordoñez, MD, Infectology, Hospital Universitario San Jorge de Pereira, Pereira, Colombia; Infectious Diseases, SES Hospital de Caldas, Manizalez, Colombia, Diego Bonilla, MD, Infectious Diseases, Clínica de Occidente, Bogotá, Colombia, Otto Sussmann, MD, Infectology, Clínica Palermo, Bogotá, Colombia; Infectious Diseases, Hospital San Rafael De Tunja, Tunja, Colombia and ABACIN Group


    C. Alvarez, None

    C. Gomez, None

    A. Montañez, None

    D. Ballen, None

    S. L. Valderrama Beltran, None

    S. Gualteros, None

    K. Ordoñez, None

    D. Bonilla, None

    O. Sussmann, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.